Early congenital cytomegalovirus could be a modifiable risk factor for childhood hyperdiploid acute lymphoblastic leukemia but more research delineating a mechanism is warranted.
Takeda UK Ltd. is pleased to announce that NICE has recommended the use of LIVTENCITY? (maribavir) as a twice daily oral treatment for adult patients with post-transplant cytomegalovirus (CMV)